Selected Publications

Nikitas J, Oughourlian T, Kashani C, Misra A, Nesbit SM, Phan J, Wang E, Gage DL, Lee A, Deng J, Steinberg ML, Jahanshahi N, Yokomizo M, Tappuni S, Suh R, Quirk M, Abtin F, and Moghanaki D: Comparison of Image Guided Thermal Ablation and Stereotactic Body Radiation Therapy for Primary Non-Small Cell Lung Cancer. 67th Annual Meeting, American Society for Radiation Oncology, San Francisco, CA Sept 2025 Notes: oral.

Juarez Casillas JE, Nikitas J, Rettig MB, Reiter RE, Lee A, Steinberg ML, Valle L, Kalbasi TR, Calais J, Czernin J, Eala MA, Tsai S, Kane N, Solanki AA, Sexton R, Duriseti S, Berenji GR, Aronson WJ, Garraway IP, Chang MG, Kwon R, Lee SP, Nickols NG, Kishan AU: Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen-defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed Therapy. Eur Urol Oncol 8(4): 893-898, Aug 2025.

Nikitas J, Ballas LK, Romero T, Lynch C, Ma TM, Valle LF, Sachdeva A, Chong N, Basehart V, Franco A, Reiter R, Saigal C, Chamie K, Litwin MS, Donin NM, Rettig M, Nickols NG, Cao M, Liauw SL, Steinberg ML, Kishan AU: Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy: A Nonrandomized Clinical Trial. JAMA Oncol 11(7): 726-734, May 2025.

Kishan AU, Jamshidian P, Nikitas J: Limitations in the meta-analysis of prostate radiotherapy-associated toxicity - Authors' reply. Lancet Oncol 26(5): e234, May 2025.

Kishan AU, Sun Y, Tree AC, Hall E, Dearnaley D, Catton CN, Lukka HR, Pond G, Lee WR, Sandler HM, Feng FY, Nguyen PL, Incrocci L, Heemsbergen W, Pos FJ, Horwitz E, Wong JK, Hoffman KE, Hassanzadeh C, Kuban DA, Arcangeli S, Sanguineti G, Supiot S, Crehange G, Latorzeff I, Kalbasi TR, Steinberg ML, Valle LF, Loblaw A, Nikitas J, Roy S, Zaorsky NG, Jia AY, Spratt DE: Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium. Lancet Oncol 26(4): 459-469, Apr 2025.

Nikitas J, Jamshidian P, Tree AC, Hall E, Dearnaley D, Michalski JM, Lee WR, Nguyen PL, Sandler HM, Catton CN, Lukka HR, Incrocci L, Heemsbergen W, Pos FJ, Roy S, Malone S, Horwitz E, Wong JK, Arcangeli S, Sanguineti G, Romero T, Sun Y, Steinberg ML, Valle LF, Weidhaas JB, Spratt D, Telesca D, Kishan AU: The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials. Lancet Oncol 26(3): 378-386, Mar 2025.

Ong WL, Romero T, Roy S, Nikitas J, Joseph D, Zapatero A, Malone S, Morgan SC, Steinberg ML, Valle LF, Zaorsky NG, Martin Ma T, Rettig MB, Nickols N, Jiang T, Reiter RE, Eleswarapu SV, Maldonado X, Sun Y, Nguyen PL, Millar JL, Martin JM, Spratt DE, Kishan AU; MARCAP Consortium Investigators: Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium. Eur Urol 87(1): 49-57, Jan 2025.

Holzgreve A, Delker A, Ells Z, Brosch-Lenz J, Unterrainer LM, Nikitas J, Zhu S, Contreras MM, Alam H, Nabong RM, Lira S, Vasilyev A, Chen L, Grogan T, Elashoff D, Meyer CA, Dahlbom M, Czernin J, Calais J. : Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule of 177Lu-PSMA Molecular Radiotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT): Study Protocol. J Nucl Med 2025.

Nikitas J, Gafita A, Benz MR, Djaïleb L, Farolfi A, Hotta M, Sonni I, Alano R, Rettig M, Shen J, Armstrong W, Grogan T, Liu S, Czernin J, Calais J: Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy. Sci Rep 14(1): 24411, Oct 2024.

Nikitas J, Kendal J, Savjani R, Jackson N, Deng J, Hernandez J, Chong N, Kadera B, Crompton J, Wessel L, Chmielowski B, Singh A, Nelson S, Dry S, Weidhaas J, Steinberg M, Bernthal N, Eilber F, Kalbasi A, Reddy K: A Phase II Trial of 5-Day Neoadjuvant Radiation Therapy for Patients with High-Risk Primary Soft Tissue Sarcoma: Long-Term Follow-up and Outcomes. 66th Annual Meeting, American Society for Radiation Oncology, Washington, D.C. Oct 2024 Notes: Oral.